Dr Jaimini Cegla
Disclosure details
Jaimini Cegla has received lecture honoraria, consultancy fees, and/or research funding from Novartis, Amgen, Sobi, Amryt, Pfizer, Daiichi Sankyo, Sanofi, Ultragenyx, Verve Therapeutics and Silence Therapeutics.Clinical Lead for the Lipids and Cardiovascular Risk Service, Consultant in Chemical Pathology and Metabolic Medicine, Imperial College Healthcare NHS Trust; Senior Clinical Lecturer, Department of Diabetes, Endocrinology and Metabolism, Imperial College London, UK
Dr Jaimini Cegla completed internal medicine training in the UK and Australia, and trained in metabolic medicine at Imperial College Trust and Guy’s and St Thomas’. She has a specialist interest in lipidology and cardiovascular risk and splits her time between clinical, laboratory and academic research roles. In her clinical role, she looks after the Hammersmith Hospital Lipid Service, a one-stop centre for the genetic diagnosis and management of lipid disorders, which also offers research facilities and access to new medications.
Dr Cegla’s current research focuses on cardiovascular risk including clinical trials of novel therapeutic agents. Dr Cegla is a member of the Medical, Scientific and Research Committee of HEART UK, the cholesterol charity. She also sits on the National Clinical Advisory Group for Lipids, which advises NHS England on strategies for CVD prevention.
In 2019, Dr Cegla led the HEART UK Consensus Statement on Lipoprotein(a). She is a local Principal Investigator for several clinical trials of Lp(a) lowering and has been involved in numerous clinical research studies of Lp(a). She is a member of the UK Lp(a) Taskforce, a diverse multi-stakeholder group that has been constituted to recognise Lp(a) as a key risk factor for atherosclerotic cardiovascular disease (ASCVD) and to raise awareness of the value of screening for Lp(a) in routine clinical practice to improve ASCVD management.
